← Eichor
Study identifier: NCT05606237 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

Condition: Myopia  ·  Sponsor: University of California, San Francisco

PhaseNA
Planned participants90
Who can joinAll sexes, 8 Years to 13 Years
Healthy volunteersYes

About this study

Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

This description comes directly from the study's public registry record.

Talk to the study team

Tiffany Chen, MD  ·  4155143503  ·  Tiffany.A.Chen@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05606237